Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: A case study in rapid clearance by extensive metabolism with low circulating metabolite exposure

Drug Metabolism and Disposition

Volumn 41, Issue 4, 2013, Pages 714-726

  Zamek Gliszczynski, Maciej J ^a   Abraham, Trent L ^a   Alberts, Jeffrey J ^a   Kulanthaivel, Palaniappan ^a   Jackson, Kimberley A ^a   Chow, Kay H ^a   Mccann, Denis J ^a   Hu, Haitao ^a   Anderson, Shelby ^a,b   Furr, Nathan A ^a   Barbuch, Robert J ^a,b   Cassidy, Kenneth C ^a  

^a ELI LILLY AND COMPANY   (United States)

^b IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [9 FLUORO 2 (PIPERIDIN 1 YLCARBONYL) 1,2,3,4 TETRAHYDRO[1,4]DIAZEPINO[6,7,1 HI]INDOL 7 YL] 4 IMIDAZO[1,2 A]PYRIDIN 3 YL 1H PYRROLE 2,5 DIONE; 3 [9 FLUORO 2 (PIPERIDIN 1 YLCARBONYL) 1,2,3,4 TETRAHYDRO[1,4]DIAZEPINO[6,7,1 HI]INDOL 7 YL] 4 IMIDAZO[1,2 A]PYRIDIN 3 YL 1H PYRROLE 2,5 DIONE C 14; 3 [9 FLUORO 2 (PIPERIDIN 1 YLCARBONYL) 1,2,3,4 TETRAHYDRO[1,4]DIAZEPINO[6,7,1 HI]INDOL 7 YL] 4 IMIDAZO[1,2 A]PYRIDIN 3 YL 1H PYRROLE 2,5 DIONE GLUCURONIDE; DRUG METABOLITE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; LY 2090314; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BILE; CASE STUDY; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; FECES; FEMALE; GENE SILENCING; HAPLORHINI; HUMAN; LIVER; LIVER MICROSOME; MALE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE; URINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BILE; DOGS; FECES; GLYCOGEN SYNTHASE KINASE 3; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; MALEIMIDES; MICROSOMES, LIVER; PROTEIN KINASE INHIBITORS; RATS; URINE;

CANIS FAMILIARIS; RATTUS;

EID: 84875823084     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048488     Document Type: Article

References (33)

1. Barbuch RJ, Campanale K, Hadden CE, Zmijewski M, Yi P, O'Bannon DD, Burkey JL, and Kulanthaivel P (2006) In vivo metabolism of [14C]ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by liquid chromatography/mass spectrometry and NMR spectroscopy. Drug Metab Dispos 34: 213-224.
2. Belinsky MG, Dawson PA, Shchaveleva I, Bain LJ, Wang R, Ling V, Chen ZS, Grinberg A, Westphal H, and Klein-Szanto A, et al. (2005) Analysis of the in vivo functions of Mrp3. Mol Pharmacol 68:160-168.
3. Benet LZ (2010) Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. Basic Clin Pharmacol Toxicol 106:162-167.
4. Boissan M, Beurel E, Wendum D, Rey C, Lécluse Y, Housset C, Lacombe ML, and Desbois- Mouthon C (2005) Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am J Pathol 167:869-877.
5. Brail LH, Gray JE, Burris HA, Simon GR, Cooksey J, Jones SF, Farrington DL, Lam T, Jackson KC, Brandt JT, and Infante JR (2011) A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in combination with pemetrexed and carboplatin [abstr 3030]. J Clin Oncol 29(Suppl):15S.
6. Burkey JL, Campanale KM, Barbuch R, O'Bannon D, Rash J, Benson C, and Small D (2006) Disposition of [14C]ruboxistaurin in humans. Drug Metab Dispos 34:1909-1917.
7. Burkey JL, Campanale KM, O'Bannon DD, Cramer JW, and Farid NA (2002) Disposition of LY333531, a selective protein kinase C beta inhibitor, in the Fischer 344 rat and beagle dog. Xenobiotica 32:1045-1052.
8. Chen C and Pollack GM (1998) Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice. J Pharmacol Exp Ther 287:545-552.
9. Chen C and Pollack GM (1999) Enhanced antinociception of the model opioid peptide [Dpenicillamine] enkephalin by P-glycoprotein modulation. Pharm Res 16:296-301.
10. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
11. Doble BW and Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116:1175-1186.
12. Grimes CA and Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65:391-426.
13. Hamilton RA, Garnett WR, and Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408-413.
14. Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, and Brouwer KL (2004) Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. J Pharmacol Exp Ther 311:1203-1210.
15. Jope RS, Yuskaitis CJ, and Beurel E (2007) Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32:577-595.
16. Kaidanovich O and Eldar-Finkelman H (2002) The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Expert Opin Ther Targets 6:555-561.
17. Klein PS and Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93:8455-8459.
18. Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, and Schinkel AH (2010) Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATPbinding cassette efflux transporters. Mol Pharmacol 77:687-694.
19. Martin M, Rehani K, Jope RS, and Michalek SM (2005) Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6: 777-784.
20. Pang KS and Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653.
21. Poulin P, Hop CE, Ho Q, Halladay JS, Haddad S, and Kenny JR (2012) Comparative assessment of In Vitro-In Vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs. J Pharm Sci 101:4308-4326.
22. Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET, and Yu Q (2005) Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res 65: 9012-9020.
23. Tian X, Li J, Zamek-Gliszczynski MJ, Bridges AS, Zhang P, Patel NJ, Raub TJ, Pollack GM, and Brouwer KLR (2007) The role of P-gp, Bcrp and Mrp2 in the biliary excretion of spiramycin. Antimicrob Agents Chemother 51:3230-3234.
24. van de Wetering K, Zelcer N, Kuil A, Feddema W, Hillebrand M, Vlaming ML, Schinkel AH, Beijnen JH, and Borst P (2007) Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Mol Pharmacol 72:387-394.
25. Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, and Cleary ML (2008) Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 455: 1205-1209.
26. Zamek-Gliszczynski MJ, Bedwell DW, Bao JQ, and Higgins JW (2012) Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics. Drug Metab Dispos 40:1825-1833.
27. Zamek-Gliszczynski MJ, Day JS, Hillgren KM, and Phillips DL (2011a) Efflux transport is an important determinant of ethinylestradiol glucuronide and ethinylestradiol sulfate pharmacokinetics. Drug Metab Dispos 39:1794-1800.
28. Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa K, and Brouwer KL (2006a) Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4- methylumbelliferyl glucuronide and sulfate in the rat. J Pharmacol Exp Ther 319:459-467.
29. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, and Brouwer KL (2008) Apparent differences in mechanisms of harmol sulfate biliary excretion in mice and rats. Drug Metab Dispos 36:2156-2158.
30. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, and Brouwer KL (2006b) Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci 27: 447-486.
31. Zamek-Gliszczynski MJ, Hoffmaster KA, Tian X, Zhao R, Polli JW, Humphreys JE, Webster LO, Bridges AS, Kalvass JC, and Brouwer KL (2005) Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1. Drug Metab Dispos 33:1158-1165.
32. Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, and Brouwer KL (2009) Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metab Dispos 37:386-390.
33. Zamek-Gliszczynski MJ, Ruterbories KJ, Ajamie RT, Wickremsinhe ER, Pothuri L, Rao MV, Basavanakatti VN, Pinjari J, Ramanathan VK, and Chaudhary AK (2011b) Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs. J Pharm Sci 100:2498-2507.